Humanin
Humanin is a small 21-amino acid mitochondrial-derived peptide known in animal-only research for neuroprotective, anti-apoptotic, and metabolic health benefits; off-label interest centers on its potential anti-aging applications, though there are no human trials and zero captured reports. The only circulating human guidance comes from a single clinician source recommending 4 mg by subcutaneous injection daily, typically run in cycles of four to twelve weeks. It has no FDA-approved indication, so all human use is off-label or compounded.
Research Evidence
Evidence shape
Humanin sits in the animal-only tier; the entire evidence base is preclinical mechanistic research, and zero human trials have been registered or completed. Only one indication is mapped and it is animal-only; the lists of populated, thin, and no-data indications are all empty, and no completed studies appear in the record. The absence of human data is total, leaving no safety data, no efficacy data, and no bridge from bench findings to clinical use.
Anecdotal efficacy
Side effects
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Price
price offers can be sorted by column
Dosing & Protocol
How Humanin is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
- Frequency
- daily
- Timing
- unspecified
- Route
- subQ
- Cycle
- unspecified
Clinician protocols dose 4 mg daily subQ (2 sources).
No structured protocol details captured for this tier yet.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Peptide feedback
0 forum repliesLive community discussion for Humanin, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.